1Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke pre- vention in atrial fibrillation: how well do random izedtrials translate into clinical practice [ J ]. JAMA, 2003,290 (20) : 2 685 - 2 692.
8Gage BF, Eby C, Milligan PE, et al. Use of pharmametice and clinical factors to predict the maintenance dose of warfarin[ J]. Thromb Haemost ,2004,91 ( 1 ) :871.
9Fuster V, Ryden LE, Cannom DS,et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation ): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [ J ]. Circulation, 2006,114 ( 7 ) : e257.
10Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatmentwit warfarin in Chinese population [ J ]. Ann Pharmacother,2000,34(12) : 1395.
4Hart RG, Pearce LA,Aguilar MI. Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007,146(12) : 857-867.
5Camm AJ,Kirehhof P,Lip GY,et al. Guidelines for the manage- ment of atrial fibrillation : the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) [J]. Eur Heart J,2010,31(19) :2369-2429.
6Guyatt GH, Norris SL, Schulman S, et al. Methodology for the de- velopment of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141(2 Suppl) :53S- 70S.
7Sun S,Wang M,Su L,et al. Study on warfarin plasma concentra- tion and its correlation with international normalized ratio[J]. J Pharm Biomed Anal, 2006,42 (2) : 218-222.
